Previous studies have reported that ginsenoside‑Rg1 (G‑Rg1) was able to mitigate the loss
of dopaminergic neurons in animal models of Parkinson's disease (PD). The present study …

To date, no drug has been proven to be neuroprotective or disease‐modifying for
Parkinson's disease (PD) in clinical trials. Here, we aimed to assess preclinical evidence of …

Aims: Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of
dopaminergic neurons in the substantia nigra (SN) and diminished dopamine levels in the …

Abstract Ginsenoside Rg1 (Rg1) is a major bioactive ingredient in Panax ginseng that has
low toxicity and has been shown to have neuroprotective effects. The objectives of the …

Background The present study investigates the effects of ginsenosides Rh 1 and Rg 2
against 6-hydroxydopamine (6-OHDA), a neurotoxin on SH-SY5Y cells and PC-12 cells. The …

Neurological diseases, including Parkinson's disease (PD), Alzheimer's disease (AD),
Huntington's disease (HD), stroke, cerebral infarction, ischemia-reperfusion injury …

Background Neurological diseases seriously affect human health, which are arousing wider
attention, and it is a great challenge to discover neuroprotective drugs with minimal side …

Emerging evidence shows that psychological stress promotes the progression of
Parkinson's disease (PD) and the onset of dyskinesia in non-PD individuals, highlighting a …

Ginsenoside Rg1 is one of the most active ingredients in ginseng, which has been reported
to protect dopaminergic neurons and improve behavioral defects in MPTP model, 6-OHDA …

Abstract Ginsenoside Rg3, extracted from Panax ginseng CA Meyer, has been shown to
possess neuroprotective properties. The present study aims to investigate the …